Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 40

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
 ended September 30, 2025, compared to $1.1 million for the same period in 2024, a decrease of approximately $105,000, or 9%. The
decline was primarily driven by reduced order volume from certain online distributors and the timing of promotional campaigns during the
quarter.

International dental revenue decreased to approximately $1.0 million in
the third quarter of 2025, compared to $1.2 million in the third quarter of 2024, a reduction of approximately $242,000, or 20%. The decrease
was largely the result of slower distributor purchasing activity in certain European markets, partially offset by resumed sales in China.

Sales in China for the three months ended September 30, 2025, were approximately
$200,000, compared to no sales in the same period of 2024. The increase reflects the Company’s successful efforts to reestablish
operations and distribution channels in the region following prior-year market disruptions.

Revenue from the medical segment totaled approximately $41,000 for the
three months ended September 30, 2025, compared to $47,000 in the same period of 2024, a decrease of approximately $6,000, or 13%. The
decline was primarily related to the timing of equipment sales and ongoing efforts to expand awareness and adoption of the Company’s
CompuFlo® Epidural and CathCheck® Systems within the U.S. pain management market.

 22 

Gross
Profit for 2025 and 2024 were as follows: 

    2025  
    2024  
    Change 
  
    Dental 
    $1,600,512  
    $1,794,041  
    $(195,529)
  
    Medical 
     40,358  
     42,179  
     (1,821)
  
    Total gross profit 
    $1,640,870  
    $1,836,220  
    $(195,350)

Consolidated gross profit for the three months ended September 30, 2025,
was approximately $1.6 million, compared to $1.8 million for the same period in 2024, representing a decrease of approximately $195,000,
or 11%. The decline in gross profit was primarily attributable to lower revenue levels during the quarter, particularly within international
and e-commerce dental sales, as well as a slight shift in the sales